Rhythm Biosciences onboards two top health experts
Rhythm Biosciences Limited (ASX:RHY) has strengthened its management team by appointing two experienced health sector executives, including Glenn Gilbert as Chief Operating Officer.
Gilbert has held various roles at the ASX-listed Medical Developments International (ASX:MVP), most recently as head of sales and marketing with oversight of global product commercialisation. His eight years of experience at MVP included mergers and acquisitions, as well as IP management.
Prior to his tenure at MVP, Gilbert held leadership roles at CSL’s biotherapeutics arm, now known as Seqirus. He holds a Monash University Bachelor of Science qualification, as well as a Graduate Certificate in Corporate Management and a Masters of Business Administration.
RHY’s second appointment is Dr Joanne Boagas as General Manager – Commercial, who brings with her 14 years’ experience in the health and medical research fields, including a decade of experience in commercialising technologies, most recently working within medical research institutes to improve and develop research programs and commercialise early-stage technologies.
Boag is also a registered Australian patent and trademark attorney, and has spent more than five years in private practice at a specialist IP firm. She has a PhD in molecular biology from the University of Western Australia.
The two appointees join an experienced team, and will work closely with General Manager of the ColoSTAT product Craig Lewis, who has spent over a decade leading innovative projects within the complex biomedical device regulatory environment including as a consultant at Planet Innovation.
Lewis is named as an inventor on four granted patents and has a Bachelor of Engineering and a Bachelor of Science from the University of Melbourne.
Adding even more to the depth of expertise among the team, CEO Trevor Lockett has wide experience in multidisciplinary research including prostate cancer gene therapies and colorectal cancer prevention.
“Both Glenn and Joanne come with excellent pedigrees,” Lockett said.
“Their broad and relevant experience will be invaluable to the company as we move to commercialise our simple and effective test for early detection of colorectal cancer.”
The company remains on track to complete the cloning of its four mixed monoclonal antibody preparations by the end of June as a component of its broader objective to develop its own antibodies and target proteins to give it control of the supply, quality and cost of its key reagents.
However, the size of the market share RHY can secure remains to be seen at this stage, so if considering this stock for your portfolio, do your own research and seek professional financial advice.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.